Globecomm Joins Amazon Web Services Partner Network
- Globecomm establishes direct access to Amazon Web Services (AWS) Direct Connect at key datacenter locations.
- Customers in U.S. Government, media and entertainment, enterprise video and the Internet of Things (IoT) can interoperate cloud-based services with Globecomm's global satellite and fiber network to reduce capital expenditure and ramp up networks and services faster.
- Globecomm's suite of Software-as-a-Service (SaaS) applications run on AWS, accessible across both AWS and Globecomm's global network.
- Globecomm's team in place to design, develop and deliver cloud-centric as well as hybrid architectures for end-to-end services and customer solutions.
HAUPPAUGE, N.Y., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Globecomm announced today that it has joined the Amazon Web Services (AWS) Partner Network (APN) as a Standard Technology Partner. This agreement will enable Globecomm to seamlessly interoperate its global satellite and fiber network with AWS's storage, compute and cloud content delivery services. With multiple direct connections to AWS, Globecomm can provision customer content, work processes and resilient network connectivity into AWS. Customers already using AWS to support their processes can benefit from seamless access to Globecomm's teleports, satellite capacity, fiber points of presence and cloud software applications running on AWS.
"We have been developing platforms and scalable customer solutions on AWS since late 2014," said Globecomm CEO Jason Juranek. "Like many of our customers, we turned to AWS for cost-effective, secure hosting of our own applications and content. With this agreement, our customers can leverage our expertise in service design and delivery for both on-premise and cloud strategies while enjoying serious savings in implementation time and overall cost."
Globecomm is currently expanding its existing global points-of-presence with AWS within the North America, Central Europe and Southeast Asia Regions. The company anticipates deploying hybrid cloud-satellite-fiber solutions for customers in media and entertainment, enterprise video and IoT. These hybrid solutions will reach beyond the edges of the network to remote facilities, ships, offshore platforms and vehicles in motion around the world.
"In the past," Mr. Juranek continued, "customers had to use traditional stacked hardware in their own data centers and then build their own teleport and operate the entire environment just to serve their markets. Between Globecomm's global fiber and teleport network, and the huge capabilities of AWS, they can develop solutions, create content and connect it globally without ever owning a single physical asset."
Globecomm is a trusted global connectivity partner for designing, managing and distributing voice, video and data solutions the most remote locations on Earth - under the most treacherous conditions. The company's multi-network Satellite, Fiber and Cellular Infrastructure is the backbone of mission-critical RF and IP communications for Government, Maritime, Media, Enterprise and Oil & Gas customers in over 100 countries. In addition to operating managed network and hosted switch services, Globecomm designs and integrates best-of-breed broadcast and OTT media solutions; complete enterprise communications and data management systems including Internet of Things applications; and on-premise and cloud-based enterprise video platforms. We proudly serve U.S. government and NGOs around the world with Morale, Welfare and Recreation (MWR) services, and assist with enterprise and government disaster relief efforts.
Headquartered in Hauppauge, NY, Globecomm has locations in Texas, Florida, Maryland, New Jersey, Virginia, the Netherlands, South Africa, Germany, Singapore, Hong Kong, the United Arab Emirates, Indonesia and Afghanistan.
Contact Information :
Peggy Stalhut; firstname.lastname@example.org
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c519268e-ceed-4208-ad8c-284d0eaeb86a
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: GLOBECOMM SYSTEMS via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
DalCor Announces Completion of Patient Enrollment in dal-GenE, the First Phase 3 Precision Medicine Cardiovascular Outcomes Trial in Coronary Heart Disease17.12.2018 09:00 | Pressemelding
LONDON and MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- DalCor today announced the completion of patient enrollment in the dal-GenE study, the first Phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease. The dal-GenE study is evaluating the efficacy of the CETP inhibitor dalcetrapib to reduce clinical cardiovascular events in patients with the AA ADCY9 genotype who have had a recent acute coronary syndrome (ACS). The study has enrolled over 6,000 patients and is being conducted in 680 sites in 32 countries. “The accelerated enrollment of patients in the dal-GenE study reflects the scientific enthusiasm and commitment among the medical community to bring the right medicine to the right patient,” said Dr. Jean-Claude Tardif from the Montreal Heart Institute. “ADCY9 genetic testing to identify the appropriate patients for treatment with dalcetrapib has the potential to provide a genetically targeted therapy to improve clinical outcomes. This approach could pave
Compuware Announces Day One Support for IBM CICS Transaction Server for z/OS V5.514.12.2018 18:02 | Pressemelding
SoftServe Achieves Machine Learning Specialization in Google Cloud Partner Program14.12.2018 13:00 | Pressemelding
Google Cloud recognizes SoftServe’s technical proficiency and proven success AUSTIN, Texas, Dec. 14, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it achieved the Machine Learning Partner Specialization in the Google Cloud Premier Partner Program. The Partner Specialization affirms SoftServe’s expertise and success building customer solutions in the machine learning field using Google Cloud Platform (GCP) technology. The Google Cloud Partner Specialization Program is designed to provide Google Cloud customers with qualified partners that demonstrate technical proficiency in the specialized solution and service areas. Specifically, the Machine Learning Specialization demonstrates SoftServe’s expertise in data exploration, preprocessing, model training, model evaluation, model deployment, online prediction, and Google Cloud’s pre-trained machine learning APIs. “We teach machines to learn, read, see and understand business data, and make
Minerals Technologies Announces Price Increases for Specialty Minerals Products in Europe14.12.2018 00:01 | Pressemelding
NEW YORK, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Specialty Minerals Inc. (“SMI”), a subsidiary of Minerals Technologies Inc., announced today that effective February 1, 2019, it will increase prices by up to 10% for all coated ultrafine precipitated calcium carbonate (PCC) from SMI’s Lifford Specialty PCC facility in Birmingham, UK, subject to individual customer contracts and market provisions. The price increases reflect increased market demand for higher performance materials, as well as significant inflation in input, raw material and logistics costs. About Minerals Technologies Inc. New York-based Minerals Technologies Inc. (MTI) is a resource- and technology-based growth company that develops, produces and markets worldwide a broad range of specialty mineral, mineral-based and synthetic mineral products and related systems and services. MTI serves the paper, foundry, steel, construction, environmental, energy, polymer and consumer products industries. The Company reported sales of $1.
Synthesio to Bring Proven Ipsos Data Science to Artificial Intelligence13.12.2018 17:03 | Pressemelding
Synthesio's Next-Generation Social Media Intelligence to Raise Unseen Insights to the Surface, Faster NEW YORK, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Synthesio, an Ipsos company, and also the leading Social Media Intelligence Suite, today announced the plans for its next-generation Artificial Intelligence (AI) engine. The project will combine Synthesio’s AI technology with Ipsos’ data science. The combination will power upcoming Synthesio capabilities to help users find insights faster, remove guesswork, and make informed business decisions across a variety of use cases. “Our goal has always been to provide customers with meaningful data, visualized so that they can make strategic business decisions,” explained Loic Moisand, CEO & Founder of Synthesio. “The less guesswork that a company has to make, and the less time that it takes users to find meaningful insights, the more time for data-backed business decisions. We are really pleased that we can leverage the data science capabilities dev
XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study13.12.2018 14:00 | Pressemelding
Biomarkers Predict Significantly Higher Rates of Treatment Response to Bermekimab in Advanced Cancer Patients AUSTIN, Texas, Dec. 13, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today the publication of findings on key biomarker analysis of colorectal cancer patients treated with bermekimab in its European Phase III study. The manuscript, entitled, “Interleukin-1 Receptor Antagonist (IL-1ra) Levels Predict Favorable Outcome after Bermekimab, a First-in-Class True Human Interleukin-1α Antibody, in a Phase III Randomized Study of Advanced Colorectal Cancer”, has been published online in the journal OncoImmunology. The findings report that patients with relatively low levels of IL-1ra or IL-6 were more likely to respond to bermekimab therapy and achieve the study’s primary endpoint. The study’s primary endpoint measured a combination of physical symptoms—pain, fatigue, anorexia and muscle wasting—which tend to worsen with advanced cancer, to assess whether these sympto